Midas Letter and C-Suite are excited to announce Midas Letter LIVE. Midas Letter highlights the stocks and stories to watch in the Canadian markets today. Host James West is a recognized authority on investing in the emerging company segment having been a regularly featured guest on Business News Network, CNBC, Bloomberg, Reuters, and CTV. James West and guests provide comprehensive fundamental & technical analysis on all trending business and investment news, while interviewing the top CEOs of all public companies and analysts with the highest reputations in the business. Midas Letter is excited to feature all investing content on C-suite.
Paradigm Capital Analyst Discusses First Biosynthetics Cannabis Conference
Paradigm Capital Equities Analyst for Healthcare and Biotechnology Rahul Sarugaser discusses the company’s biosynthetics cannabis conference, which will be held on April 15 and is the first of its kind in the industry. Sarugaser notes that while no company is producing biosynthetic cannabinoids at scale yet, biosynthetics have the potential to bring down the costs of goods. Sarugaser provides an overview of the process and the benefits of using yeast, E. coli, or algae as a chassis. While the industry has not been able to identify the best chassis yet, he suggests the best biosynthetic cannabinoids are a result of the best combination of chassis, intellectual property, and scientific team. Sarugaser highlights Ginkgo Bioworks Inc as the segment leader and notes the company’s partnership with cannabis heavyweight Cronos Group Inc (TSE:CRON) (NASDAQ:CRON) (FRA:7CI) to develop cultured cannabinoids has the potential to produce biosynthetic cannabinoids at scale.